Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.

@article{Wang2004CellularIF,
  title={Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.},
  author={Jinjuan Wang and O. Press and C. Lindgren and P. Greenberg and S. Riddell and Xiaojun Qian and Christian Laugen and A. Raubitschek and S. Forman and M. Jensen},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2004},
  volume={9 4},
  pages={
          577-86
        }
}
  • Jinjuan Wang, O. Press, +7 authors M. Jensen
  • Published 2004
  • Biology, Medicine
  • Molecular therapy : the journal of the American Society of Gene Therapy
  • Humoral immunotherapy using the monoclonal anti-CD20 antibody rituximab induces remissions in approximately 60% of patients with relapsed follicular lymphoma; however, most patients eventually relapse despite continued expression of CD20 on lymphoma cells. We have hypothesized that cellular immunotherapy targeting CD20(+) cells might provide a more effective mechanism for eliminating lymphoma cells than anti-CD20 antibodies and are therefore investigating the utility of cytotoxic T lymphocytes… CONTINUE READING
    87 Citations
    Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3ζ recombinant gene
    • 19
    Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma
    • Fei Chen, Chuming Fan, +6 authors X. Lai
    • Biology, Medicine
    • Medical science monitor : international medical journal of experimental and clinical research
    • 2015
    • 8
    • PDF
    Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
    • 35
    • Highly Influenced
    • PDF
    Killing of non‐Hodgkin lymphoma cells by autologous CD19 engineered T cells
    • 25

    References

    SHOWING 1-10 OF 36 REFERENCES
    Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
    • 511
    • PDF
    In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    • 257
    CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.
    • 98
    Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.
    • 349
    • PDF